New blood cancer therapy successful in three-quarters of trial patients
1 min read
Image caption: The new treatment is currently under application for review by the FDA. Depositphotos. Article by Rich Haridy. New Atlas – December 11, 2022.
New data from an ongoing Phase 1/2 clinical trial has revealed an experimental immunotherapy led to successful response rates in 73% of patients suffering from multiple myeloma, a deadly form of blood cancer. Based on this promising data, an application to the US Food and Drug Administration (FDA) has been filed to bring the drug to market. […]